: iStockAnalyst.com Symbols Feed

Senesco Technologies Inc. (SNT) Moves Promising Drug Toward Clinical Trial

Fri, 31 Jul 2009 14:18:04 GMT

Senesco Technologies Inc. secured additional financing to continue research into genetic technologies designed to deter apoptosis, or programmed cell death, in humans. This technology is applicable in many different diseases including cancer, glaucoma, and cardiovascular problems. The financing will come in three pieces and will total $705,000. The company will issue 783,332 shares of its common stock at $0.90 per share, and two separate warrant issues. The first warrant will grant the right to purchase up to 705,000 shares of common stock, at an exercise price of $0.01 per share, exercisable immediately. The balance of the warrants will grant the right to purchase up to 714,794 shares of common stock at an exercise price of $0.60 per share. These warrants are exercisable 6 months from the date of issuance. Cato Holding Company, one of the purchasers of the stock and warrants, has also agreed to cancel $175,000 of[More...]

A Dozen Stocks To Watch, Some Breakouts Look Interesting

Mon, 16 Jun 2008 20:32:33 GMT

A dozen stocks I’m watching, again, no Supernovas, nothing ideal, just watching and preying:[More...]

Thumping Thursday & Ominous Omens

Fri, 10 Aug 2007 13:53:06 GMT

OptionSage submits:“Today was the best day I’ve had since joining Phil’s Stock World. I want to thank Phil, Happy, Z, Sage, Dragon, Optrader and everyone here for being so helpful to me. You guys are GREAT! Can’t wait for tomorrow.” GregWhen the markets drop and we make a lot of money we know that others are not so fortunate and Phil tends to be somewhat embarrassed at proclaiming how well we’re doing in bearish markets since we often tend to be in the minority. However, I am going to indulge in congratulating the group on another job well done with the Dow down 387 points, the NASDAQ[More...]

Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing

Thu, 30 Jul 2009 19:57:00 GMT

Senesco Technologies, Inc. today announced that, on July 29, 2009, the Company entered into definitive purchase agreements with certain members of Senesco's Board of Directors and certain accredited investors, including Cato Holding Company, which is the venture capital affiliate of Cato Research Ltd., a global contract research and development organization currently assisting Senesco with its SNS-101 development program with the emphasis on initiating a Phase I clinical trial for multiple myeloma.[More...]

Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing

Fri, 10 Jul 2009 13:10:00 GMT

Senesco Technologies, Inc. today announced that, on July 9, 2009, the Company entered into a definitive purchase agreement with Partlet Holdings Ltd. for the issuance and sale of up to 1,111,111 shares of its common stock at a price of $0.90 per share, warrants to purchase an aggregate of up to 1,000,000 shares of common stock, which warrants are exercisable immediately at an exercise price of $0.01 per share and warrants to purchase an aggregate of up to 2,055,555 shares of common stock, which warrants are exercisable 6 months from the date of issuance at an exercise price of $0.60 per share . In connection with the private placement, the Company anticipates that it will receive aggregate proceeds in the amount of $1,000,000.[More...]

ArborGen and Senesco Announce Wood Quality Results

Tue, 07 Jul 2009 11:56:00 GMT

ArborGen, LLC, a leader in forest tree improvement technologies, today announced wood quality results from ongoing field trials that are utilizing technology in-licensed from Senesco Technologies, Inc. . The two companies had previously announced that trees that incorporate Senesco technology have shown significantly enhanced growth rates in 3-year-old field trials.[More...]

Senesco Technologies, Inc. Announces the Appointment of Dr. Harlan W. Waksal, M.D. as Chairman of the Board of Directors and the Addition of Mr. Warren J. Isabelle, CFA to its Board of Directors

Tue, 09 Jun 2009 11:58:00 GMT

Senesco Technologies, Inc. today announced the appointment, effective June 8, 2009, of its current Board member, Dr. Harlan Waksal, M.D., to serve as Chairman of the Board, succeeding Mr. Rudolf Stalder, who has been the Company's Chairman since January 2000. Mr. Stalder will continue serving on the Board and also serve as a member of a newly formed Executive Committee that includes Dr. Harlan Waksal, Mr. Christopher Forbes and Mr. Rudolf Stalder.[More...]

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

Wed, 27 May 2009 12:09:00 GMT

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy[More...]

Senesco Announces H1N1 Influenza Survival Test Results in Mice

Tue, 26 May 2009 11:56:00 GMT

Senesco Announces H1N1 Influenza Survival Test Results in Mice[More...]

Senesco Technologies Reports Third Quarter Fiscal 2009 Financial Results

Mon, 04 May 2009 13:50:00 GMT

NEW BRUNSWICK, N.J., May 4 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) today reported financial results for the three months ended March 31, 2009.
This decrease in net loss was primarily the result of a decrease in operating expenses, which was partially offset by an increase in non-cash expenses associated with the outstanding convertible notes that were issued during the year ended June 30, 2008.
Senesco announced results of maximum tolerated dose, preclinical

[More...]

Senesco Technologies Reports Second Quarter Fiscal 2009 Financial Results

Wed, 18 Feb 2009 11:57:00 GMT

Senesco Technologies, Inc. today reported financial results for the three months ended December 31, 2008.[More...]

Senesco Technologies to Present at the 11th Annual BIO CEO & Investor Conference

Thu, 05 Feb 2009 11:57:00 GMT

Senesco Technologies, Inc. today announced that the Company will be presenting at the 11th Annual BIO CEO & Investor Conference, which is being held at the Waldorf-Astoria Hotel in New York City from February 9th - 10th, 2009. Bruce Galton, Chief Executive Officer of Senesco, will deliver the Company's corporate presentation on Monday, February 9th, at 9:30 AM ET.[More...]

Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate

Tue, 03 Feb 2009 11:59:00 GMT

Senesco Technologies, Inc. today announced results of efficacy, toxicological and dose-finding studies in mice for its potential multiple myeloma drug candidate, SNS-01. SNS-01 is a nano-encapsulated combination therapy of Factor5A and an siRNA against Factor 5A. These studies, undertaken to determine the efficacy, maximum tolerated dose and the feasibility of long-term intravenous administration of SNS-01, were performed at the University of Waterloo, Ontario, Canada.[More...]